SLOW FE supplies ferrous sulfate for the treatment of iron deficiency and iron deficiency anemia with a significant reduction in the incidence of the common side effects of oral iron preparations. The wax matrix delivery system of SLOW FE is designed to maximize the release of ferrous sulfate in the duodenum and the jejunum where it is best tolerated and absorbed. SLOW FE has been clinically shown to be associated with a lower incidence of constipation, diarrhea and abdominal discomfort when compared to an immediate release iron tablet 1 and a leading sustained release iron capsule. 2

Formula   Each tablet contains: Active Ingredient: 160 mg. dried ferrous sulfate USP, equivalent to 50 mg. elemental iron. Inactive Ingredients: cetostearyl alcohol, FD&C Blue No. 2 aluminum lake, hydroxypropyl methylcellulose, lactose, magnesium stearate, polysorbate 80, talc, titanium dioxide, yellow iron oxide.

Dosage:   ADULTS--one or two tablets daily or as recommended by a physician. A maximum of four tablets daily may be taken. CHILDREN--one tablet daily. Tablets must be swallowed whole.

Warning:   Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Warning:   The treatment of any anemic condition should be under the advice and supervision of a physician. As oral iron products interfere with absorption of oral tetracycline antibiotics, these products should not be taken within two hours of each other. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.

Blister packaged for your protection. Do not use if individual seals are broken.

How Supplied:   Child-resistant blister packages of 30, 60, and 90.

Do Not Store Above 30°C (86°F). Protect From Moisture.

Tablets made in Great Britain

Novartis Consumer Health, Inc.

Summit, NJ 07901-1312


NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug' identity should be verified by chemical analysis.


  1. Brock C et al. Adverse effects of iron supplementation: A comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets. Clin Ther. 1985; 7:568-573.
  2. Brock C, Curry H. Comparative incidence of side effects of a wax-matrix and a sustained-release iron preparation. Clin Ther. 1985; 7:492-496.